Oura Ring 5 Valuation Triples as CEO Secretly Tests New AI Sleep Drug
Helsinki — Oura Health’s next-gen Oura Ring 5 just shattered its Series F target at a $5.2 billion valuation, double market estimates, after leaked internal tests show its embedded AI can simulate a proprietary sleep compound—slashing recovery time by 40%. Multiple Fortune 500 CEOs have placed blind pre-orders, betting the hardware becomes the de facto executive health controller. Competitors are scrambling, but Oura’s closed-loop algorithm remains patent-locked through 2029.